Comparing the current results to its competitors, Pavmed Inc reported Revenue increase in the 2 quarter 2026 by 135.71 % year on year, while most of its competitors have experienced contraction in revenues by -10.55 %, achieved in the same quarter.
Pavmed Inc 's Comment on Competition and Industry Peers
The company competes in the U.S. market for esophageal adenocarcinoma (EAC) and pre-cancer testing against procedure-based detection technologies such as upper endoscopy and biomarker multi-cancer early detection assays. Its EsoCheck device competes with other manufacturers' devices designed to collect cell samples from targeted esophageal regions, including EndoSign, commercialized by Cyted, and Cytosponge. The company also faces competition in recruiting personnel and acquiring complementary technologies. In the cancer patient care market, the Veris Cancer Care Platform competes with other digital care platforms that offer features such as electronic health record (EHR) integration and remote patient monitoring. While the company is not aware of other implantable physiologic monitors with biologic sensors, it acknowledges that competitors may be developing similar devices.
Microbot Medical Inc is a medical device company that focuses on the research, development, and commercialization of surgical solutions. Their business model revolves around creating innovative robotic technologies and tools for minimally invasive surgeries, catering to various medical specialties.
Myomo Inc's business model revolves around the development and commercialization of advanced medical devices, specifically myoelectric orthotics for individuals with neuromuscular disorders.
Nuo Therapeutics Inc's business model revolves around developing and commercializing innovative biologic therapies aimed at improving healthcare outcomes for patients. They focus on the research, development, and marketing of new therapeutic products, primarily in the wound care sector.
Pulse Biosciences Inc's business model focuses on the development and commercialization of proprietary technology platforms, specifically in the field of nano-pulse stimulation (NPS) technology.
Avita Medical Inc is a medical technology company that specializes in regenerative medicine. Their business model focuses on developing and commercializing innovative products for the treatment of burns, chronic wounds, and other skin-related conditions.
Sources:
Pavmed Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Pavmed Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
